Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 6, Issue 261, Pages 261ra152-261ra152
Publisher
American Association for the Advancement of Science (AAAS)
Online
2014-11-06
DOI
10.1126/scitranslmed.3009318
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents
- (2015) Thomas Reiner et al. NEOPLASIA
- HIF-1α Inhibition Reverses Multidrug Resistance in Colon Cancer Cells via Downregulation of MDR1/P-Glycoprotein
- (2014) Jianfang Chen et al. PLoS One
- Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
- (2013) Shigehira Saji BIODRUGS
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
- (2013) Ziyad Binkhathlan et al. CURRENT CANCER DRUG TARGETS
- Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles
- (2013) N. Kamaly et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo
- (2013) Greg M. Thurber et al. Nature Communications
- Engineering Particles for Therapeutic Delivery: Prospects and Challenges
- (2012) Yan Yan et al. ACS Nano
- Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
- (2012) Nazila Kamaly et al. CHEMICAL SOCIETY REVIEWS
- Tolerability and Pharmacokinetics of a New P-Glycoprotein Inhibitor, HM30181, in Healthy Korean Male Volunteers: Single- and Multiple-Dose Randomized, Placebo-Controlled Studies
- (2012) Tae-Eun Kim et al. CLINICAL THERAPEUTICS
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
- (2012) Luis A. Diaz Jr et al. NATURE
- Intravital Imaging
- (2011) Mikael J. Pittet et al. CELL
- Solid-phase synthesis of BODIPY dyes and development of an immunoglobulin fluorescent sensor
- (2011) Marc Vendrell et al. CHEMICAL COMMUNICATIONS
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells
- (2010) Zhenyu Ding et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- In Vivo Imaging in Cancer
- (2010) J. Condeelis et al. Cold Spring Harbor Perspectives in Biology
- Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel
- (2009) Jin-Oh Kwak et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis
- (2009) Lavinia Nardinocchi et al. Molecular Cancer
- Automatic Segmentation of High-Throughput RNAi Fluorescent Cellular Images
- (2008) Pingkun Yan et al. IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
- (2008) T. Okouneva et al. MOLECULAR CANCER THERAPEUTICS
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
- (2008) S. Dhar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started